Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ocular Therapeutix, Inc.
Randomized, multi-center, double-masked, vehicle-controlled, Phase 1/2 study to evaluate the safety, tolerability, and efficacy of OTX-CSI in subjects with dry eye disease. The subjects will be followed for approximately 16 weeks after product insertion
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Dry eye disease diagnosis
VAS eye dryness severity score ≥ 30.
You may not be if
Are unwilling to discontinue use of contact lenses
Are unwilling to withhold use of artificial tears.
